Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025
Regeneron reported Q4 2024 earnings today and declared its first-ever dividend of $0.88 per quarter. Click here to know what makes REGN stock a compelling buy.
Regeneron Pharma Q4 Earnings Crush Estimates, Initiates Dividend And Additional Stock Buyback Program
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $12.07, up 2% year-over-year, beating the consensus of $11.29. The company reported sales of $3.79 billion, up 10%,
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback program, sending its shares up 2.
Regeneron Launches Dividend Program, Boost Stock Buybacks
Regeneron Pharmaceuticals is stepping up its shareholder returns with the launch of a quarterly dividend and a $3 billion increase to its stock-buyback program. Regeneron on Tuesday said its board declared an initial quarterly dividend of 88 cents, payable March 20 to shareholders of record Feb. 20.
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,
Regeneron Pharmaceuticals Q4 Profit Decreases, But Beats Estimates
Regeneron Pharmaceuticals (REGN) announced earnings for fourth quarter that decreased from the same period last year but beat the
BioPharma Dive
38m
Amgen obesity drug on hold; Regeneron sets first dividend
The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.
BioSpace
1d
Regeneron Misses on Eylea, Dupixent Sales; Issues First-Ever Dividends
Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...
6h
Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings
Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...
Investor's Business Daily on MSN
20h
Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend
Regeneron stock jumped Tuesday after the biotech giant topped Wall Street's December-quarter calls on the back of its cancer drug Libtayo.
23h
on MSN
Regeneron’s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea
Regeneron Pharmaceuticals Inc.’s stock rose 4.9% Tuesday to put it on track for its biggest one-day gain in almost two years, ...
1h
Regeneron Pharmaceuticals, Inc. Is Being Sued For Securities Law Violations And The Schall Law Firm Urges Shareholders With Losses To Reach Out
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a ...
FiercePharma
1d
Regeneron's Libtayo reaches blockbuster status and has potential for more growth: execs
Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
LIBTAYO
Calendar year
Feedback